Oncternal Therapeutics (Oncternal Therapeutics) Operating Cash Flow per Share : $-10.95 (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics Operating Cash Flow per Share?

Oncternal Therapeutics's operating cash flow per share for the three months ended in Dec. 2023 was $-2.18. Oncternal Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.95.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 14.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 40.80% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 37.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Oncternal Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

ONCT' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -92.9 Med: 22.5 Max: 64.2
Current: 14.1

During the past 13 years, Oncternal Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 64.20% per year. The lowest was -92.90% per year. And the median was 22.50% per year.

ONCT's 3-Year OCF Growth Rate is ranked better than
60.29% of 1239 companies
in the Biotechnology industry
Industry Median: 3.6 vs ONCT: 14.10

Oncternal Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Oncternal Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Operating Cash Flow per Share Chart

Oncternal Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-32.45

-17.24

-10.78

-13.96

-10.94

Oncternal Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-3.18	-3.75	-3.16	-1.87	-2.18

Competitive Comparison of Oncternal Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Oncternal Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncternal Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Price-to-Operating-Cash-Flow falls into.

Oncternal Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Oncternal Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-32.164	/	2.940
	=	-10.94

Oncternal Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-6.419	/	2.949
	=	-2.18

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.95

Oncternal Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics (Oncternal Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

GTU:Germany

Address

12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130

Website

https://www.oncternal.com

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Executives

Gunnar F. Kaufmann	officer: Chief Scientific Officer	C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji	officer: Chief Medical Officer	12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer	director, officer: President, CEO
Richard G Vincent	officer: Chief Financial Officer	C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt	officer: General Counsel/Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan	officer: Chief Technology Officer	12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen	director	12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter	director	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner	director	2292 FARADAY AVENUE, CARLSBAD CA 92008
Shanghai Pharmaceuticals Holding Co., Ltd.	10 percent owner	C/O ONCTEMAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceuticals (hk) Investment Ltd	10 percent owner	C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceutical (usa) Inc.	10 percent owner	C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Hazel M Aker	officer: General Counsel	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Man Cho	director	C/O ONCTERNAL THERAPEUTICS, INC., SUITE 300, SAN DIEGO CA 92130